OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

  • End date
    Jun 26, 2022
  • participants needed
  • sponsor
    Otonomy, Inc.
Updated on 26 July 2021
hearing impairment
hard of hearing


The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise hearing impairment.

Condition Sensorineural hearing loss, Hearing Loss, Auditory Loss and Deafness, Hearing Impairment
Treatment Placebo, OTO-413
Clinical Study IdentifierNCT04129775
SponsorOtonomy, Inc.
Last Modified on26 July 2021


Yes No Not Sure

Inclusion Criteria

Subject has audiometrically-defined normal hearing or up to moderately severe hearing impairment
Subject has self-reported difficulty hearing in noisy environments for at least 6 months prior to Screening
Subject exhibited a speech-in-noise hearing deficit in at least one ear

Exclusion Criteria

Subject is pregnant or lactating
Subject has the following hearing disorders or any other hearing disorders that may impact the efficacy assessments or safety of the subject in the opinion of the Investigator: Meniere's disease, congenital hearing loss, or genetic sensorineural hearing loss
Subject has a cochlear implant or consistently uses a hearing aid
Subject has worked at least 5 years as a professional musician or has had at least 15 years of formal musical training
Subject self-reports bothersome, subjective tinnitus and is consistently aware of their tinnitus throughout much of the waking day
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note